

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 15.11.2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

**Subject:** Submission under Regulation 52(1), 52(4), 52(5), 52 (7) and 54 (2) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.


Dear Sir/Madam,


With reference to the subject matter, please find enclosed the following:

- i. The unaudited financial results of the Company for the half year ended 30<sup>th</sup> September, 2019 along with the Limited Review Report for that period issued by the Statutory Auditors SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015
- iii. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015.
- iv. A statement pursuant to Regulation 52(7) of SEBI (LODR), 2015.
- v. A disclosure under Regulation 54(2) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

  
Ganeshprasad Gupta  
Company Secretary and Compliance Officer  
Membership no. A33925



# Shankarlal Jain & Associates LLP

## Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,  
The Board of Directors,  
Genlink Pharma Solutions Private Limited,  
(Formerly known as Genlink Pharma Investments Private Limited)  
Mumbai.

Dear Sir,

Re: Limited Review of Un-audited Standalone Financial Statements for the Half Year ended September 30, 2019 in respect of Genlink Pharma Solutions Private Limited, (Formerly known as Genlink Pharma Investments Private Limited)

### Introduction

We have reviewed the accompanying standalone un-audited standalone financial statements of Genlink Pharma Solutions Private Limited, (Formerly known as Genlink Pharma Investments Private Limited) for the half year ended September 30, 2019 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these standalone financial statements based on our review.

### Scope of Review

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Engagements to Review of Interim Financial Information performed issued by the Independent Auditor of the Entity* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

### Basis of Qualified Opinion

Refer note no. 9 on long term borrowings amounting to Rs. 272,661,626/- which includes loan against property of Rs. 22,661,626/-, of which is subject to confirmation and reconciliation, if any.



**Branch Office** : 2nd Floor, Boraj Arcade, Opp. Hanuman Mandir, G.S. Road, Ulubari, Guwahati - 781 007. ASSAM  
**Contact Partner** : Bineet Bagaria, B. Com., F.C.A. • Tel.: 0361-2460472 • Mobile : 09864067403

# Shankarlal Jain & Associates LLP

Chartered Accountants




12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

## Conclusion

In our opinion and to the best of our information and according to the explanation given to us, except for the effect of the matter described in the Basis of Qualified Opinion paragraph above and based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards i.e Ind AS prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



Place: Mumbai

Date: 14<sup>th</sup> November, 2019

For Shankarlal Jain & Associates LLP  
Chartered Accountants  
Registration No. 109901W/W100082

Satish Jain  
Partner

Membership No. 048874

UDIN : 19048874AAAAGG3414

**Branch Office** : 2nd Floor, Boraj Arcade, Opp. Hanuman Mandir, G.S. Road, Ulubari, Guwahati - 781 007. ASSAM  
**Contact Partner** : Bineet Bagaria, B. Com., F.C.A. • Tel.: 0361-2460472 • Mobile : 09864067403

**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
 (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)  
**STANDALONE BALANCE SHEET AS AT 30 September 2019**

( Amount in INR)

Particulars	Note No.	As at 30 Sept 2019 (Unaudited)	As at 31 March 2019 (Audited)
<b>I. ASSETS</b>			
<b>1 Non-current assets</b>			
(a) Property, Plant & Equipment	2	3,01,77,280	3,04,33,702
(a) Non-current investments	3	24,89,95,479	24,89,95,479
<b>2 Current assets</b>			
(a) Trade receivables	4	6,31,050	14,40,400
(a) Cash and cash equivalents	5	5,300	6,601
(b) Other current assets	6	2,58,434	34,168
<b>TOTAL</b>		<b>28,00,67,543</b>	<b>28,09,10,350</b>
<b>II. EQUITY AND LIABILITIES</b>			
<b>1 Equity</b>			
(a) Share capital	7	1,00,000	1,00,000
(b) Other Equity	8	23,47,192	21,27,852
<b>2 Non-current liabilities</b>			
(a) Financial Liabilities			
(i) Long-term borrowings	9	27,26,61,626	27,29,48,634
<b>3 Current liabilities</b>			
(a) Financial Liabilities			
(i) Other financial liabilities	10	47,41,225	51,55,864
(b) Current tax liabilities & Provisions	11	2,17,500	5,78,000
<b>TOTAL</b>		<b>28,00,67,543</b>	<b>28,09,10,350</b>

For Genlink Pharma Solutions Private limited



Anand Shah  
 Chairman  
 DIN: - 00597145  
 Navi Mumbai  
 Date :



Susheel Koul  
 Managing Director  
 DIN: - 00925887  
 Navi Mumbai

ut

BIM

**GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**  
**(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)**  
**STANDALONE BALANCE SHEET AS AT 30 September 2019**

( Amount in INR)

Particulars	Refer Note No	As at 30 Sept 2019 (Unaudited)	As at 31 March 2019 (Audited)
<b>I REVENUE</b>			
Revenue from operations	12	19,80,000	78,70,000
<b>Total Revenue</b>		<b>19,80,000</b>	<b>78,70,000</b>
<b>II EXPENSES</b>			
Finance costs	13	11,73,114	7,97,338
Depreciation and amortisation expenses	14	2,56,422	2,54,306
Other expenses	15	2,53,701	7,00,055
<b>Total expenses</b>		<b>16,83,237</b>	<b>17,51,699</b>
<b>III Profit/(Loss) before tax (I-II)</b>		<b>2,96,763</b>	<b>61,18,301</b>
<b>IV Tax expense</b>			
Current tax		77,158	12,20,000
(Excess)/Short Provision for Tax		267	521
<b>V Profit/(Loss) after tax (III-IV)</b>		<b>2,19,338</b>	<b>48,97,780</b>
<b>VI Earnings Per Share</b>			
-Basic & Diluted		<b>21.93</b>	<b>489.78</b>

For Genlink Pharma Solutions Private Limited



Anand Shah  
Chairman  
DIN: - 00597145  
Navi Mumbai  
Date :



Susheel Koul  
Managing Director  
DIN: - 00925887  
Navi Mumbai

BIM

ht

November 15, 2019

To  
The Board of Directors,  
Genlink Pharma Solutions Private Limited  
1704, 17th Floor, Kesar Solitaire,  
Plot No. 5, Sector 19,  
Sanpada, Navi Mumbai - 400 705,  
Maharashtra, India

Sub: Certificate of Debenture Trustee under Regulation 52(5) of SEBI (LODR) Regulations, 2015 for September 30, 2019

Dear Sir/Madam

In compliance of the requirement of Chapter V, Regulation 52(4) and 52(5) of the Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 it is certified as under:

We, Vistra ITCL (India) Limited, are acting as a Debenture Trustee for the debenture programme of Secured Redeemable, Listed, Non-Convertible Debenture issue aggregating to Rs 25,00,00,000/- (Rupees Twenty Five Crores Only) of Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited), "the Company"


With reference to the above, we have received the following documents and noted its contents:

1. Unaudited financial results for the half year ended 30<sup>th</sup> September, 2019 along with Limited Review Report issued by the Statutory Auditor for that period.
2. Disclosure pursuant to Regulation 52 (4) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended 30<sup>th</sup> September, 2019.

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You.

Yours sincerely,  
For Vistra ITCL (India) Limited



Authorized signatory  
Place: Mumbai

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)


## DISCLOSURE UNDER REGULATION 52(4) OF SEBI (LODR), 2015

- 1. Credit rating** - The Company's NCDs have been rated as "ACUITE BB-" by Acuite Ratings & Research Limited. There has been no change in the credit rating of the Company.
- 2. Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
- 3. Debt-equity ratio - 111.60 Times**
- 4. Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
- 5. Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
- 6. Next due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence no due date is applicable.
- 7. Debt service coverage ratio - 0.91 Times**
- 8. Interest service coverage ratio - 1.25 Times**
- 9. Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares.
- 10. Capital redemption reserve/debenture redemption reserve - NIL**
- 11. Net worth** - The net worth of the Company is - 24,47,192/-
- 12. Net profit after tax**  
Net profit after tax of the Company is Rs 2,19,338/-
- 13. Earnings per share**  
Earnings per share of the Company is Rs 21.93/-  
**For Genlink Pharma Solutions Private Limited**

  
Ganeshprasad Gupta

Company Secretary and Compliance Officer

Membership no. A33926



Office: 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India  
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email [genlinkinfo@gmail.com](mailto:genlinkinfo@gmail.com) [www.genlinkpharma.com](http://www.genlinkpharma.com)

CIN: U74110 MH 2016 PTC 280765


# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## DISCLOSURE PURSUANT TO REGULATION 52 (7) OF THE SEBI (LODR), 2015

We hereby state that for the half year ended 30<sup>th</sup> September, 2019, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

For Genlink Pharma Solutions Private Limited

  
Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
Membership no. A33925





# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)


## DISCLOSURE UNDER REGULATION 54 OF SEBI (LODR), 2015

We hereby state that the Company maintains as on 30<sup>th</sup> September, 2019 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 563,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Genlink Pharma Solutions Private Limited.
2. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

For Genlink Pharma Solutions Private Limited

  
Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
Membership no. A33925



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 15.11.2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 56(1) (d) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed herewith the disclosure pursuant to the subject Regulation for the half year ended 30<sup>th</sup> September, 2019.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited



Ganeshprasad Gupta  
Company Secretary and  
Compliance Officer  
Membership no. ACS33925

# Shankarlal Jain & Associates LLP

Chartered Accountants



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sjainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sjainindia.com

## TO WHOMSOEVER IT MAY CONCERN

This is to certify that **GENLINK PHARMA SOLUTIONS PRIVATE LIMITED**, (CIN U74110MH2016PTC280765) having its registered office at 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No 5, Sector 19, Sanpada, Navi Mumbai – 400 705 has an Asset Cover Ratio of 1.25 times as at September 30th, 2019 based on the details and documents provided to us which is tabulated herein below:

Sr. No	Particulars	Unit	Amount (Rs)
a)	Non-Convertible Debentures (NCD) Value	Rs.	25,00,00,000/-
b)	Number of shares of Enaltec Labs Pvt. Ltd. pledged	No.	5,75,343
c)	Valuation (As per Valuation Report dated 05 <sup>th</sup> January, 2017 Enaltec Labs Pvt Ltd. issued by CA Prashant Moliya and which is accepted as it is).	Rs./Share	544.52
d)	Value of Shares pledged ( Rs 544.52 * 5,75,343)	Rs	31,32,85,770/-
e)	Security Cover (Rs Lacs 3,133/ 2500)	Ratio	1.25 times

\*Shares include 11,846 shares pledged by promoters (Mr. Anand Shah – 5, 923 equity shares and Mr. Susheel Koul 5923 equity shares)

Since the Company has issued Zero Coupon Debentures, Debt Equity Ratio, Debt Service Coverage Ratio and Interest Service Coverage Ratio are not applicable in the above mentioned NCD.

The above mentioned Company has utilized Debenture Subscription Receipts of Rs. 25,00,00,000/- (Rs Twenty Five Crores) for purchase of equity shares (5,63,497 equity shares) of Enaltec Labs Private Limited.



Branch Office : 2nd Floor, Boraj Arcade, Opp. Hanuman Mandir, G.S. Road, Ulubari, Guwahati - 781 007. ASSAM  
Contact Partner : Bineet Bagaria, B. Com., F.C.A. • Tel.: 0361-2460472 • Mobile : 09864067403

**Shankarlal Jain & Associates LLP**  
**Chartered Accountants**



12, Engineer Building, 265 Princess Street, Mumbai - 400 002, India E-mail : info@sjainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sjainindia.com

The above mentioned Company has not transferred any amount to Debenture Redemption Reserve as at 30<sup>th</sup> September, 2019 in the absence of adequacy of profits.

The above has been verified from the details and documents produced before us.

**For Shankarlal Jain & Associates LLP**  
**Chartered Accountants**

**Registration No. 109901WW100082**

**Satish Jain**  
**Partner**

**Membership No. 048874**

**UDIN : 19048874AAAAGI2609**

**Place: Mumbai**

**Date: 14<sup>th</sup> November, 2019**

**Branch Office : 2nd Floor, Boraj Arcade, Opp. Hanuman Mandir, G.S. Road, Ulubari, Guwahati - 781 007. ASSAM**  
**Contact Partner : Bineet Bagaria, B. Com., F.C.A. • Tel.: 0361-2460472 • Mobile : 09864067403**